<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ren, Hua</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Capecitabine Compared with Capecitabine Plus Oxaliplatin Chemoradiotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Preliminary findings demonstrate that patients with rectal cancer receiving radiotherapy with a combination of capecitabine and oxaliplatin have better local regional control compared with those receiving capecitabine plus radiotherapy. This article presents interim data from the ongoing phase 3 open-label Adjuvant Treatment of Concurrent R and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer trial [NCT00714077].</style></abstract><number><style face="normal" font="default" size="100%">31</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>